Last updated: May 27, 2026
Cefotetan is a second-generation cephalosporin antibiotic. In practice, “suppliers” split into three lanes: (1) API and key intermediates used by injectables manufacturers, (2) finished sterile cefotetan products sold through distributors, and (3) contract manufacturing organizations (CMOs) that handle sterile fill-finish and labeling under third-party authorization. A complete, reliable supplier map depends on the exact product form (e.g., cefotetan disodium vs. other salt forms), strength (typically injectable vials), market (US vs. EU vs. other), and whether the buyer needs API supply, sterile manufacturing, or both.
What suppliers provide cefotetan API and key intermediates?
The highest-confidence supplier-identification route for cefotetan API is the combination of FDA Drug Master File (DMF) holders, Orange Book-listed finished-product applicants, and public sterile manufacturing disclosures. Without those specific listings for the exact cefotetan strength and NDA/ANDA product, a full supplier roster cannot be stated with the precision required for procurement, licensing, or litigation due diligence.
What API form is typically traded?
- Cefotetan is marketed as cefotetan disodium in injectable formats. Buyers generally source either:
- cefotetan disodium API, or
- cefotetan synthetic intermediates plus a conversion/finishing step handled by the supplier or the finished-dose manufacturer.
- Sterile products require separate qualification for reconstitution compatibility, vial closure integrity, and terminal sterilization or aseptic processing controls, which sit downstream from API supply.
What “supplier” category matters for sourcing?
- API-only vendors (chemical manufacturers or intermediate suppliers).
- Integrated pharma suppliers that own both API and finished drug substance/drug product.
- Contract manufacturers supplying the sterile product while the API is sourced from a separate upstream vendor.
Which companies supply cefotetan finished injectable products in the US?
In the US, finished-dose “suppliers” map to the NDA/ANDA sponsor listed on the product label and Orange Book. Finished injectables supply chains can also include contract sterilization and fill-finish partners, but the commercial entity responsible for market supply is the approved application holder and the listed manufacturer on the label.
Orange Book and label-based mapping
- For a procurement-ready list, you match:
- product name and strength,
- application holder,
- manufacturer of record,
- and distributor chain for specific lot availability.
- Without the specific cefotetan NDA/ANDA identifiers and the current Orange Book entries for the marketed strengths, a definitive company list cannot be produced.
How do cefotetan suppliers differ for distributors versus hospitals?
Distribution is often separate from manufacturing. Hospitals typically buy via GPO channels, while specialty distributors may handle hospital procurement and cold-chain or controlled logistics.
What to expect in the distribution layer
- Multiple distributors may carry the same manufacturer’s labeled product.
- Substitute NDCs often exist if there are multiple strengths or packaging configurations for the same application.
- Lot traceability depends on the label manufacturer and NDC mapping.
What is the regulatory status of cefotetan that drives supplier eligibility?
Supplier eligibility hinges on:
- FDA approval status of the finished dosage form,
- current Good Manufacturing Practice (cGMP) standing for drug substance and sterile product,
- and whether the product is actively marketed or discontinued.
US requirements that affect sourcing
- Sterile manufacturing and container-closure integrity testing for injectables.
- API quality controls: beta-lactam-related impurity profile and process-related impurities.
- Stability and shelf-life controls tied to formulation and packaging configuration.
What patent or exclusivity conditions affect cefotetan manufacturing and sourcing?
Cefotetan is an established antibiotic with substantial history in the market. Patent or exclusivity status determines who can legally market an identical branded product and which generics may have entered under ANDA, including potential Paragraph IV challenges. Supplier availability for generic vs. reference is driven by:
- what is still covered by unexpired patents,
- whether exclusivities remain, and
- what patent challenges were resolved via settlement.
Why this matters for “who can supply”
- If there are active Orange Book patents or method-of-use coverage tied to a specific formulation or use, some generic entrants may be delayed or licensed.
- If no listed patents remain, supply tends to diversify to multiple ANDA holders and CMOs.
What manufacturing barriers limit additional cefotetan suppliers?
For sterile injectables like cefotetan, the supply bottlenecks typically come from:
- sterile fill-finish capacity for beta-lactam products,
- validated reconstitution performance and compatibility across diluents,
- impurity control in beta-lactam APIs,
- and regulatory inspection outcomes at sterile facilities.
Sterile fill-finish and beta-lactam constraints
- Dedicated lines or validated cross-contamination controls are common for beta-lactam antibiotics.
- Batch release testing includes sterility, endotoxin, particulate matter, potency, and degradation profile.
What generic entry risks exist for cefotetan and how does that impact suppliers?
Generic competition can expand supplier count, but entry risks remain tied to:
- patent-driven launch timelines,
- manufacturing validation complexity,
- and site inspection readiness.
Paragraph IV and settlement outcomes
- If there were recent patent settlements, they would typically show up as delayed launches or authorized generic arrangements.
- Without the current patent landscape for the specific cefotetan NDCs in scope, launch risk cannot be mapped to named suppliers.
Key Takeaways
- Cefotetan “supplier” lists must be product-specific (strength, salt form, NDC) and market-specific (US vs EU) because sourcing splits across API vendors, finished-product application holders, and sterile CMOs.
- A procurement-grade supplier roster requires Orange Book and label-manufacturer mappings for the exact cefotetan finished dose being sourced, plus DMF holders or API vendor disclosures.
- Sterile beta-lactam manufacturing constraints and cGMP inspection status are the most common practical barriers that limit cefotetan supplier count.
FAQs
- How can I identify cefotetan API suppliers for cefotetan disodium injectable?
- Which Orange Book listings determine who can legally supply cefotetan in the US?
- What sterile manufacturing requirements constrain cefotetan injectable supply?
- Do cefotetan generics require Paragraph IV challenges to launch?
- How do NDC manufacturer changes affect cefotetan hospital procurement and lot traceability?
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. US Food and Drug Administration.
- FDA Drug Master Files (DMF) database. US Food and Drug Administration.
- FDA Approved Drug Products and Biological Product Information. US Food and Drug Administration.
